Skip to content

Broad-spectrum antivirals

Viruses are a threat to our health, lives and livelihoods. We’re developing a family of broad-spectrum antivirals to treat viral diseases, and for pandemic protection.

Our Work

Currently, approved antiviral drugs are only available for 11 of the more than 220 viruses known to infect humans. We’re changing that by developing a family of broad-spectrum therapeutics to treat a much wider range of clinical and priority viruses.

Latest News

After spending the last three years in R&D, developing and optimising our broad-spectrum antiviral platform, in September 2023 we launched a Series A capital raise to secure the funds needed to complete our pre-clinical studies.

Support Us

Our goal is to end viral disease, and we need your help to achieve it. You can support our vital research by donating and spreading the word about what we are doing. Your support is very much appreciated – and every dollar helps.

We're working on new, genuinely broad-spectrum antivirals.

Kimer Med is a biotech start-up, located in Nelson, New Zealand. We’re creating new, broad-spectrum antiviral drugs. Our antivirals are a derivative of DRACO, which was effective in vitro against 15 different viruses in 11 tissue types, and against Influenza H1N1 in mice.

So far, we have achieved significant success in vitro against 10 different human viruses, and identified a lead candidate to target Dengue and other flaviviruses. A recent in vivo study supports the efficacy and safety of our compounds.

Antivirals are needed to deal with viral diseases, and for pandemic protection

The harm to human life caused by pathogenic viruses is on an enormous scale! In years gone by, viruses such as smallpox killed hundreds of millions, perhaps over 300 million as late as the 20th century. The polio virus paralysed over 15,000 people annually. The 1918 flu pandemic killed upwards of 100 million. Then there was Covid-19.

Read more about our efforts to address this age-old problem.

Read the Latest News and Articles from Kimer Med

Kimer Med Signs Contract With Battelle Memorial Institute To Pioneer Antiviral Drug Advances

Kimer Med signs contract with Battelle Memorial Institute to pioneer antiviral drug advances

Media Release Nelson, New Zealand – 8 March 2024 – Kimer Med, a Nelson biotech start-up, announced it has signed a contract valued at up to USD$750,000 (NZD$1.3 million) with…

Image Of A CMV Virion Crossed Out In A Red Circle

Could a cure for CMV result in longer lifespans?

While standard antiviral therapies can suppress active viral replication, there’s no existing treatment that can eradicate latent infection, meaning there’s no cure for many prevalent viral diseases. Viral infection has…

NZ’s Pandemic Preparedness Report – Our Assessment

NZ’s Pandemic Preparedness report – our assessment

New Zealand’s Infectious Disease Research Platform ‘Te Niwha’ has released a substantial report entitled “Likely future pandemic agents and scenarios: An epidemiological and public health framework”. The report was commissioned…

Join the conversation

You can contribute to our efforts to end viral disease. Talk with our co-founders, other professionals and interested parties about the development of our new broad-spectrum antivirals.

Back To Top